Compare FULC & VMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | VMD |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.8M | 465.4M |
| IPO Year | 2019 | 2018 |
| Metric | FULC | VMD |
|---|---|---|
| Price | $3.88 | $9.72 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $16.38 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 355.6K |
| Earning Date | 04-27-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.14 |
| EPS | N/A | ★ 0.13 |
| Revenue | N/A | ★ $270,280,000.00 |
| Revenue This Year | N/A | $17.88 |
| Revenue Next Year | N/A | $14.98 |
| P/E Ratio | ★ N/A | $73.23 |
| Revenue Growth | N/A | ★ 20.52 |
| 52 Week Low | $2.83 | $6.05 |
| 52 Week High | $15.74 | $12.61 |
| Indicator | FULC | VMD |
|---|---|---|
| Relative Strength Index (RSI) | 49.05 | 23.61 |
| Support Level | $3.41 | $9.26 |
| Resistance Level | $4.02 | $10.05 |
| Average True Range (ATR) | 0.15 | 0.41 |
| MACD | 0.05 | -0.33 |
| Stochastic Oscillator | 82.19 | 8.12 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.